Biotechnology
FAPON presents at 41st Annual J.P. Morgan Healthcare Conference
SHENZHEN, China, Jan. 16, 2023 /PRNewswire/ -- FAPON, a leading life sciences company, announced that Mr. Jielun ZHU, the company's Chief Financial Officer (CFO) and Chief Investment Officer (CIO), has presented at the 41st Annual J.P. Morgan Healthcare Conference and shared FAPON's development, ...
2023-01-16 22:09
4097
CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China
SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, andHuadong Medicine ( Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co....
2023-01-16 18:00
2972
SD Biosensor Successfully Finishes JP Morgan Healthcare Conference
* Entering the US market in earnest by acquiring Meridian * Expanding into a direct sales system in 10 countries within the year * Launching plans, including the new product, 'STANDARD M10 FAST RT-PCR, CGMS' SEOUL, South Korea, Jan. 13, 2023 /PRNewswire/ -- SD Biosensor, Inc. (KS137310), Sou...
2023-01-13 15:11
3106
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
- Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel 3-month ext...
2023-01-12 17:00
2027
iNtRON is finalizing the SAL200 Tech Transfer
* Including the contract transfers of the external studies planned for the
successful out-licensing and commercialization of SAL200 BOSTON and SEOUL,
South Korea, Jan. 11, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",
www.intodeworld.com
2023-01-12 09:34
2597
Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future
* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. * Designed b...
2023-01-11 08:01
2935
Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations
SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for sunvozertinib for the treatment of advanced NSCLC with EGFR exon20ins...
2023-01-10 17:03
2847
FAPON to attend 41st Annual J.P. Morgan Healthcare Conference
SHENZHEN, China, Jan. 10, 2023 /PRNewswire/ -- FAPON, a leading life sciences company, today announces that its senior executive management will attend the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jielun ZHU, CFO & CIO of FAPON, will be making a corporate presentation o...
2023-01-10 16:37
2794
SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'
SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...
2023-01-10 07:00
2396
SK Inc. hosts "SK Bio Night" in San Francisco to expand global partnerships
* SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners * Newly appointed executives to lead SK's biopharmaceutical businesses to attend the event * SK Inc. to promote the competitiveness of K-bio and pro...
2023-01-10 07:00
2173
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tre...
2023-01-09 23:25
3125
SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia
* The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) * SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -...
2023-01-09 21:00
3114
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ap...
2023-01-09 20:00
2258
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...
2023-01-08 14:17
3913
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...
2023-01-07 17:29
4566
Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD
Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medici...
2023-01-06 21:00
2467
Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...
2023-01-06 18:00
1995
SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock
- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South Korea, Jan. 5, 2023 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, today announced that Mr.Donghoon Lee, the Chief Executive Officer and President of SK Biophar...
2023-01-06 09:10
1973
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program * Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties * Collaboration based on synergies between Adcendo ...
2023-01-05 09:00
1730
Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Chairman and CEO, Dr.Dajun Yang, has accep...
2023-01-05 09:00
2908
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8004